Note 16 - Subsequent Events	12 Months Ended
Dec. 31, 2025
Notes to Financial Statements
Subsequent Events [Text Block]	*Note 16.* Subsequent Events At-the-Market Offering** From January 2, 2026, through March 13, 2026, the Company raised approximately $0.1 million in gross proceeds ($0.1 net of offering fees) from the sale of 18,880 shares of the Company’s common stock through its At-the-Market offering program. Since the initial shelf-registration in August 2024, the Company has, as of the date of this filing, raised approximately $10.8 million in gross proceeds under the At-the-Market offering program, issuing approximately 10.7 million shares, for net proceeds of approximately $10.4 million. *Standby Equity Purchase Agreement* From January 2, 2026, through March 13, 2026, the Company raised approximately $0.3 million in gross proceeds ($0.3 million net of offering fees) from the sale of 130,184 shares of the Company’s common stock through its standby equity purchase agreement facility. Since the initial registration in May 2025, the Company has, as of the date of this filing, raised approximately $0.4 million in gross proceeds under the standby equity purchase agreement, issuing 138,184 shares, for net proceeds of approximately $0.3 million. *Nasdaq Decision Letter* On January 20, 2026, the Company received a letter from Nasdaq confirming that the Company has regained compliance with the minimum bid price requirement of the Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Rule").

Note 16 - Subsequent Events

12 Months Ended

Dec. 31, 2025

Note 16. Subsequent Events

At-the-Market Offering

From January 2, 2026, through March 13, 2026, the Company raised approximately $0.1 million in gross proceeds ($0.1 net of offering fees) from the sale of 18,880 shares of the Company’s common stock through its At-the-Market offering program. Since the initial shelf-registration in August 2024, the Company has, as of the date of this filing, raised approximately $10.8 million in gross proceeds under the At-the-Market offering program, issuing approximately 10.7 million shares, for net proceeds of approximately $10.4 million.

Standby Equity Purchase Agreement

From January 2, 2026, through March 13, 2026, the Company raised approximately $0.3 million in gross proceeds ($0.3 million net of offering fees) from the sale of 130,184 shares of the Company’s common stock through its standby equity purchase agreement facility. Since the initial registration in May 2025, the Company has, as of the date of this filing, raised approximately $0.4 million in gross proceeds under the standby equity purchase agreement, issuing 138,184 shares, for net proceeds of approximately $0.3 million.

Nasdaq Decision Letter

On January 20, 2026, the Company received a letter from Nasdaq confirming that the Company has regained compliance with the minimum bid price requirement of the Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Rule").

SeaStar Medical Holding Corp 10-K